InDevR's VaxArray platform to tackle measles-Rubella vaccines

(InDevR, Inc.) InDevR announced today that it will pursue proof of concept development for new VaxArray potency assays for measles (M) and rubella vaccines sponsored by the Bill& Melinda Gates Foundation. The long-term objective is to create in vitro measles and rubella potency assays in order to deliver high quality MR vaccines to market faster and with lower production costs. The project will leverage the multiplexed VaxArray platform, which was first developed and validated for more efficient potency testing of influenza vaccines.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news